Zusammenfassung
Die Gesundheitspolitik beschäftigt sich in aller Regel nicht mit medizinischen Detailfragen, sondern verweist auf die „Fachebene“. Das mag sich zunehmend ändern, und die Gründe für einen solchen Trend liegen im Zweifelsfall in der gesundheitsökonomischen Dimension. Dies ist auch der Grund, warum eine gesundheitspolitische Betrachtung der modernen, atypischen Neuroleptika gefordert wird. Der Grund liegt in den 5- bis lOfach höheren Tagesbehandlungskosten, und dies angesichts der sog. Kostenexplosion im Gesundheitswesen. Daraus ist bisher jedoch kein für diese Neuroleptika spezifisches, gesundheitspolitisches Problembewußtsein entwickelt worden.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Davies LM, Drummond MF (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 162:38–42
Essock SM, Hargreaves WA, Covell NH, Goethe J (1996) Clozapine’s effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacol Bull 32:683–697
Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L (1996) Clozapine eligibility among state hospital patients. Schizophr Bull 22:15–25
Freeman HL (1997) Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies. Int Clin Psychopharmacol 12: S11–S17
Hamilton SH, Revicki DA, Genduso LA, Besley CM (1998) Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18: 41–49
Henke KD, Martin K, Behrens C (1997) Direkte und indirekte Kosten von Krankheiten in der Bundesrepublik Deutschland 1980 und 1990. Z f Gesundheitswiss 5:123–145
Kennedy BL, Schwab JJ (1997) Utilization of medical specialists by anxiety disorder patients. Psychosomatics 38:109–112
Kissling W (1994) Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand Suppl 89:16–24
Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997) Depression in the community: The first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12: 19–29
Moller HJ, Boyer P, Fleurot O, Rein W (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol. Psychopharmacology 132:396–401
Naber D (1998) Subjective experiences of schizophrenic patients treated with antipsychotic medication. Int Clin Psychopharmacol 13: 41–45
Nabulsi AA, Braus AJ, Mack RJ et al. (1996) Reduction of hospital days in sertindole treated patients — one year findings. (Abstract) APA Congress
Revicki DA (1997) Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 22: 256–266
Satterlee W, Dellce M,Beasley C (1996) Effectiveness of olanzapine in long-term continuation treatment. (Abstract) Boca Raton
Song F (1997) Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials. J Psychopharmacol 11: 65–71
Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB (1997) Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety. Int Clin Psychopharmacol 12: 29–35
Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CJ, Tollefson GD (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407–418
van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124: 168–175
Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schröder J, Rein W, Benkert O (1998) Amisulpride versus flupentixole in schizophrenia with predominantly positive symptomatology—a double-blind controlled study comparing a selective D2-like to a mixed Dl-/D2-like antagonist. The amisulpride study group. Psychopharmacology 137: 223–232
Wyatt RJ (1994) The cost of schizophrenia-productive person years: making direct and indirect costs understandable. Neuropsychopharmacology 10: 597
Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, and the Sertindole Study Group (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–791
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
Fritze, J. (1999). Therapie mit atypischen Neuroleptika aus gesundheitspolitischer Sicht: Versuch einer gesundheitsökonomischen Analyse. In: Möller, HJ., Müller, N. (eds) Atypische Neuroleptika. Steinkopff. https://doi.org/10.1007/978-3-642-93709-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-93709-5_11
Publisher Name: Steinkopff
Print ISBN: 978-3-7985-1179-8
Online ISBN: 978-3-642-93709-5
eBook Packages: Springer Book Archive